LLS Announced Upcoming Free Patient Teleconferences

CML: Understanding Your Treatment Options
Register for this free telephone/webcast education program taking place on Thursday, April 29, 2010, from 1:00 - 2:00pm ET with featured speaker David L. Porter, M.D., Professor of Medicine, University of Pennsylvania School of Medicine, Director, Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA.
Participants will have the opportunity to ask the presenter a question during the program. This program is sponsored by The Leukemia & Lymphoma Society and is supported by grants from Novartis Oncology. www.novartisoncology.com

Childhood Leukemia & Lymphoma: Update on Treatment
and Follow-up Care
Register for this free telephone/webcast education program taking place on Tuesday, May 4, 2010, from 1-2pm ET with featured speaker Sima Jeha, M.D., Director, Leukemia/Lymphoma, Developmental Therapeutics Department of Oncology at St. Jude Children's Research Hospital, Memphis, TN.
Participants will have the opportunity to ask the presenter a question during the program.

Financial Health Matters
This new internet webcast is intended for patients, their family members and healthcare professionals, and this program focuses on the financial impact a cancer diagnosis can have, the various insurance programs and resources that are available and sources of information and support on financial health matters related to a cancer diagnosis. You can view the webcast or print/read the program transcript and slides of this program.
This free educational program is for patients, caregivers and healthcare professionals. This is a complimentary online continuing education activity.
914.949.5213 | www.LLS.org

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap